Meloxicam: A reappraisal of pharmacokinetics, efficacy and safety

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 12, 2005, Pages 2117-2140

  Gates, Brian J ^a   Nguyen, Trang T ^a   Setter, Stephen M ^a   Davies, Neal M ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Cyclooxygenase; Meloxicam; Non steroidal anti inflammatory drug; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; ANTACID AGENT; CELECOXIB; CIMETIDINE; COLESTYRAMINE; CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; DEXTROMETHORPHAN; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYALURONIC ACID; INDOMETACIN; KETOCONAZOLE; LITHIUM; MELOXICAM; MOBICOX; MOVATEC; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PLACEBO; PROSTACYCLIN; PROTEOGLYCAN; REACTIVE OXYGEN METABOLITE; ROFECOXIB; SULFAPHENAZOLE; THROMBOXANE; TOLBUTAMIDE; UNINDEXED DRUG;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIPYRETIC ACTIVITY; CARDIOTOXICITY; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DIGESTIVE SYSTEM ULCER; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DYSPEPSIA; EDEMA; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HUMAN; HYPERTENSION; NEPHROTOXICITY; NONHUMAN; OSTEOARTHRITIS; PATIENT COMPLIANCE; PRESCRIPTION; REVIEW; RHEUMATOID ARTHRITIS; THROMBOEMBOLISM;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; CYCLOOXYGENASE 2 INHIBITORS; DRUG INTERACTIONS; GASTROINTESTINAL DISEASES; HUMANS; THIAZINES; THIAZOLES;

EID: 27744579858     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.12.2117     Document Type: Review

References (89)

1. DAVIES NM, MCLACHLAN J: Pharmacokinetic and pharmacodynamic considerations of cyclooxygenase-2 inhibitors. Clin. Ger. (2000) 8(5):49-62.
2. DAVIES NM, SKJODT NM: Clinical pharmacokinetics of meloxicam. A cyclooxygenase-2 preferential nonsteroidal anti-inflammatory drug. Clin. Pharmacokinet. (1999) 36(2):115-126.
3. NOBLE S, BALFOUR JA: Meloxicam. Drugs (1996) 51(3):424-430.
4. BOEHRINGER INGELHEIM, CORPORATION: Mobic® (meloxicam) prescribing information. Boehringer Ingelheim Corporation, Germany (2004).
5. ENGELHARDT G, BOGEL R, SCHNITZER C, UTZMANN R: Meloxicam. Influence on arachidonic acid metabolism part 1 in vitro findings. Bioch. Pharmacol. (1996) 51:21-28.
6. ENGELHARDT G, BOGEL R, SCHNITZER C, UTZMANN R: Meloxicam. Influence on arachidonic acid metabolism part 2 in vivo findings. Bioch. Pharmacol. (1996) 51:29-38.
7. PANARA MR, RENDA G, SCIULLI MG et al.: Dose-dependent inhibition of platelet cyclooxygenase-1 and monocytes cyclooxygenase-2 by meloxicam in healthy subjects. J. Pharmacol. Exp. Ther. (1999) 290(1):276-280.
8. ENGELHARDT G, HOMMA D, SCHLEGEL K, UTZMANN R, SCHNITZLER C: Anti-inflammatory, analgesic, antipyretic, and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favorable gastrointestinal tolerance. Inflamm. Res. (1995) 44:423-433.
9. ENGELHARDT G, HOMMA D, SCHNITZLER C: Meloxicam. A potent inhibitor of adjuvant arthritis in the Lewis rat. Inflamm. Res. (1995) 44(12):548-555.
10. STICHTENOTH DO, WAGNER B, FROLICH JC: Effect of selective inhibition of the inducible cyclooxygenase on rennin release in healthy volunteers. J. Inv. Med. (1998) 46(6):290-296.
11. SAWDY RJ, SULLIVAN MHF, BENNETT PR: The effects of non-steroidal anti-inflammatory compounds on human myometrial contractility. Eur. J. Obs. Gyn. Rep. Biol. (2003) 109:33-40.
12. PATOIA L, SANTUCCI L, FURNO P et al.: A 4-week, double-blind, parallel-group study to compare the gastrointestinal effects of meloxicam 7.5 mg, meloxicam 15 mg, piroxicam 20 mg and placebo by means of faecal blood loss, endoscopy and symptom evaluation in healthy volunteers. Br. J. Rheumatol. (1996) 35(Suppl. 1):61-67.
13. BLOT L, MARCELIS A, DEVOGELAER JP, MANICOURT DH: Effects of diclofenac, aceclofenac, and meloxicam on the metabolism of proteoglycans and hyaluronan in osteoarthritic human cartilage. Br. J. Pharmacol. (2000) 131:1413-1421.
14. PITT B, PEPINE C, WILLERSON JT: Cyclooxygenase-2 inhibition and cardiovascular events. Circulation (2002) 106:167-169.
15. RINGER HM, TRACEY JB, SOUHRADA M et al.: Effects of meloxicam on platelet function in healthy adults. A randomized, double-blind, placebo-controlled trial. J. Clin. Pharmacol. (2002) 42:881-886.
16. DE MEIJER A, VOLLAARD H, DE METZ M et al.: Meloxicam, 15 mg/day, spares platelet function in healthy volunteers. Clin. Pharmacol. Ther. (1999) 66:425-430.
17. VAN KRAAIJ DJW, HOVESTAD-VITTERIAND AHI, DE METZ M et al.: A comparison of the effects of nabumetone versus meloxicam on serum thromboxan B2 and platelet function in healthy volunteers. Br. J. Clin. Pharmacol. (2002) 53:644-647.
18. DAVIES NM, JAMALI F: COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter. J. Pharm. Pharm. Sci. (2004) 7:332-336.
19. KUEHN BM: FDA panel: keep COX-2 drugs on market: black box for COX-2 labels, caution urged for all NSAIDs. JAMA (2005) 293:1571-1572.
20. VAN ANTWERPEN P, NEVE J: In vitro comparative assessment of the scavenging activity against three reactive oxygen species of non-steroidal anti-inflammatory drugs from the oxicam and sulfoanilide families. Eur. J. Pharmacol. (2004) 496:55-461.
21. TURCK D, BUSCH U, HEIZEL G, JARJES H: Clinical pharmacokinetics of meloxicam. Arzneim-Forsch. Drug. Res. (1997) 47(1):253-258.
22. HANFT G, TURCK D, SCHEUERER S et al.: Meloxicam oral suspension: a treatment alternative to solid meloxicam formulations. Inflamm. Res. (2001) 50(Suppl. 1):S35-S37.
23. BUSCH U, HEINZEL G, NARJES H: Effect of food on pharmacokinetics of meloxicam, a new non steroidal anti-inflammatory drug (NSAID). Agent Actions (1991) 32(1-2):52-53.
24. TURCK D, BUSCH U, HEINZEL G et al.: Basic clinical pharmacokinetics of meloxicam, a new NSAID (Abstr.) Scand. J. Rheumatol. (1994) S98:A120.
25. NARJES H, TURCK D, BUSCH U et al.: Pharmacokinetics and tolerability of meloxicam after i.m adimistration. Br. J. Clin. Pharmacol. (1996) 41(2):135-139.
26. FLEISCHMANN R, IQBAL I, SLOBODIN G: Meloxicam. Expert Opin. Pharmacother. (2002) 3(10):1501-1512.
27. HOWARD SS, WITHNEY BAIRD: Meloxicam and selective COX-2 inhibitors in the management of pain in the palliative care population. Am. J. Hosp. Pall. Car. (2003) 20(4):297-304.
28. BUSCH U, SCHMID J, HEINZEL G: Pharmacokinetics of meloxicam in animals and the relevance to humans. Drug Met. Disp. (1998) 26(6):576-584.
29. CHESNE C, GUYOMARD C, GUILLOUZO A et al.: Metabolism of meloxicam in human liver involves cytochromes P4502C9 and 3A4. Xenobiotic (1998) 28(1):1-13.
30. SCHMID J, BUSCH U, HEINZEL G et al.: Pharmacokinetics and metabolic pattern after intravenous infusion and oral administration to healthy subjects. Drug Metab. Dipos. (1995) 23(11):1206-1213.
31. BURGOS-VARGAS R, FOELDVARI I, THON A et al.: Pharmacokinetics of meloxicam in patients with juvenile rheumatoid arthritis. J. Clin. Pharmcol. (2004) 44:866-8722.
32. TURCK D, SCHWARZ A, HOFFLER D: Pharmacokinetics of meloxicam in patients with end stage renal failure on haemodialysis: a comparison with healthy volunteers. Eur. J. Clin. Pharmacol. (1996) 51(3-4):309-313.
33. BOULTON-JONES JIM, GEDDES CG, HEINZEL G et al.: Meloxicam pharmacokinetics in renal impairment. Br. J. Clin. Pharmacol (1997) 43(1):35-40.
34. BEVIS PJR, BIRD HA, LAPHAM G: An open study to assess the safety and tolerability of meloxicam 15 mg in subjects with rheumatic disease and mild renal impairment. Br. J. Rheumatol. (1996) 35(Suppl. 1):56-60.
35. BUSCH U, HEINZEL G, NARJES H, NEHMIZ G: Interaction of meloxicam with cimetidine, maalox, or aspirin. J. Clin. Pharmacol. (1996) 36(1):79-84.
36. RYN JV, KINK-EIBAND M, KURITSCH I et al.: Meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers. J. Clin. Pharmacol. (2004) 44:777-784.
37. DEGNER FL, HEINZEL G, NARJES H, TURCK D: The effect of meloxicam on the pharmacokinetics of beta-acetyl-digoxin. Br. J. Clin. Pharmacol. (1995) 40(5):486-8.
38. HUBNER G, SANDER O, DEGNER FL, TUCK D, RAU R: Lack of pharmacokinetic interaction of meloxicam with methotrexate in patients with rheumatoid arthritis. J. Rheumatol. (1997) 24(5):845-851.
39. MULLER FO, MIDDLE MV, SCHALL R et al.: An evaluation of the interaction of meloxicam with frusemide in patients with compensated chronic cardiac failure. Br. J. Clin. Pharmacol. (1997) 44:393-398.
40. BUSCH U, HEINZEL G, NARJES H: The effect of cholestyramine on the pharmacokinetics of meloxicam, a new non steroidal anti-inflammatory drug (NSAID), in man. Eur. J. Clin. Pharmacol. (1995) 48(3-4):269-272.
41. HOSIE J, DISTEL M, BLUHMKI E: Meloxicam in osteoarthritis: a 6-month, double-blind comparison with diclofenac sodium. Br. J. Rheum. (1996) 35(1):39-43.
42. LINDEN B, DISTEL M, BLUHMKI E: A double-blind study to compare the efficacy and safety of meloxicant 15 mg with piroxicam 20 mg in patients with osteoarthritis of the hip. Br. J. Rheum. (1996) 35(1):35-38.
43. GOEI THE HS, LUNDT B, DISTEL MR, BLUHMKI E: A double-blind, randomized trial to compare meloxicant 15 mg with diclofenac 100 mg in the treatment of osteoarthritis of the knee. Osteoarthr. Cart. (1997) 5:283-288.
44. LUND B, DISTEL M, BLUHMKI E: A double-blind, randomized, placebo-controlled study of efficacy and tolerance of meloxicam treatment in patients with osteoarthritis of the knee. Scand. J. Rheumatol. (1998) 27:32-37.
45. YOCUM D, FLEISCHMANN R, DALGIN P, CALDWELL J, HALL D: Safety and efficacy of meloxicam in the treatment of osteoarthritis, a 12-week, double-blind, multiple dose, placebo-controlled trial. Arch. Intern. Med. (2000) 160:2947-2954.
46. VALAT JP, ACCARDO S, REGINSTER JY, WOUTERS M, HETTICH M, LIEU PL, THE INTERNATIONAL MELOXICAM LUMBAR OSTEOARTHRITIS GROUP: A comparison of the efficacy and tolerability of meloxicam and diclofenac in the treatment of patients with osteoarthritis of the lumbar spine. Inflamm. Res. (2001) 50(1):S30-S34.
47. BUNYARATAVEJ N, KEOROCHANA S, PITHKUL S: Safety and efficacy of meloxicam 7.5 mg in the treatment of osteoarthritis in thai patients. J. Med. Assoc. Thai. (2001) 84(2):S542-S546.
48. REGINSTER JY, DISTEL M, BLUHMKI E: A double-blind, three-week study to compare the efficacy and safety of meloxicam 7.5 mg and meloxicam 15 mg in patients with rheumatoid arthritis. Br. J. Rheumatol. (1996) 35(1):17-21.
49. HUSKISSON EC, GHOZLAN R, KURTHEN R, DEGNERS FL, BLUHMKI E: A long-term study to evaluate the safety and efficacy of meloxicam therapy in patients with rheumatoid arthritis. Br. J. Rheumatol. (1996) 35(1):29-34.
50. WOJTULEWSKI JA, SCHATTENKIRCHNER M, BARCELO P et al.: A six-month double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis. Br. J. Rheumatol. (1996) 35(1):22-28.
51. LEMMEL EM, BOLTEN W, BURGOS-VARGAS R et al.: Efficacy and safety of meloxicam in patients with rheumatoid arthritis. J. Rheumatol. (1997) 24(2):282-290.
52. COMBE B, VELICICITAT P, GARZON N, BLUHMKI E: Comparison of intramuscular and oral meloxicam in rheumatoid arthritis patients. Inflamm. Res. (2001) 50(1):S10-S16.
53. COLBERG K, HETTICH M, SIGMUND R, DEGNER F: The efficacy and tolerability of an 8-day administration of intravenous and oral meloxicam: a comparison with intramuscular and oral diclofenac in patients with acute lumbago. Curr. Med. Res. Op. (1996) 13(7):363-377.
54. BOSCH H, SIGMUND R, HETTICH M: Efficacy and tolerability of intramuscular and oral meloxicam in patients with acute lumbago: a comparison with intramuscular and oral piroxicam. Curr. Med. Res. Op. (1997) 14(1):29-38.
55. VIDAL L, KNEER W, BATURONE M, SIGMUND R: Meloxicam in acute episodes of soft-tissue rheumatism of the shoulder. Inflamm. Res. (2001) 50(1):S24-S29.
56. CHENG TT, LAI HM, CHIU CK, CHEN YC: A single-blind, randomized, controlled trial to assess the efficacy and tolerability of rofecoxib, diclofenac sodium, and meloxicam in patients with acute gouty arthritis. Clin. Ther. (2004) 26(3):399-406.
57. RUPERTO N, NIKISHINA I, PACHANOV ED et al.: A randomized, double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis. Arthr. Rheum. (2005) 52(2):563-572.
58. AUVINET B, ZILLER R, APPELBOOM T, VELICITAT P: Comparison of the onset and intensity of action of intramuscular meloxicam and oral meloxicam in patients with acute sciatica. Clin. Ther. (1995) 17(6):1078-1090.
59. DREISER RL, LE PARC JM, VELICITAT P, LLEU PL: Oral meloxicam is effective in acute sciatica: two randomized, double-blind trials versus placebo or diclofenac. Inflamm. Res. (2001) 50(1):S17-S23.
60. BARTHEL T, BAUMANN B, NOTH U, EULERT J: Prophylaxis of heterotopic ossification after total hip arthroplasty. Acta. Orthop. Stand. (2002) 73(6):611-614.
61. LEGENSTEIN R, BOSCH P, UNGERSBOCK A: Indomethacin versus meloxicam for prevention of heterotopic ossification after total hip arthroplasty. Arch. Orthop. Traum. Surg. (2003) 123:91-94.
62. DE MELLO NR, BARACAT EC, TOMAZ G et al.: Double-blind study to evaluate efficacy and safety of meloxicam 7.5 mg and 15 mg versus mefenamic acid 1500 mg in the treatment of primary dysmenorrhea. Acta Obstet. Gynecol. Sound (2004) 83:667-673.
63. THOMPSON JP, SHARPE P, KIANI S, OWEN-SMITH O: Effect of meloxicam on postoperative pain after abdominal hysterectomy. Br. J. Anaesth. (2000) 84(2):151-154.
64. AKARSU T, KARAMAN S, AKERCAN F, KAZANDI M, YUCEBILGIN MS, FIRAT V: Pre-emptive meloxicam for postoperative pain relief after abdominal hysterectomy. Clin. Exp. Obst. Gyn. (2004) 31(2):133-136.
65. NEKOOFAR MH, SADEGHIPANAH M, DEHPOUR AR: Evaluation of meloxicam (a COX-2 inhibitor) for management of postoperative endodontic pain: a double-blind placebo-controlled study. J. Endodont. (2003) 29(10):634-637.
66. DAWOOD AL-WAILI NS: Sublingual meloxicam for renal colic. Urol. Int. (2001) 67:119-120.
67. PROUSE PJ, BEVIS PJ, BLUHMKI E, DISTEL M: Evaluation of the safety, tolerability, and efficacy of meloxicam tablets in patients with osteoarthritis. Clin. Ther. (1996) 18:429-439.
68. FURST DE, KOLBA KS, FLEISCHMANN R et al.: Dose response and safety study of meloxicam up to 22.5 mg daily in rheumatoid arthritis: a 12 week multicenter, double-blind, dose response study versus placebo and diclofenac. J. Rheumatol. (2002) 29:436-446.
69. DISTEL M, MUELLER C, BLUHMKI E, FRIES J: Safety of meloxicam: a global analysis of clinical trials. Br. J. Rheumatol. (1996) 35(Suppl. 1):68-77.
70. SCHOENFELD P: Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials. Am. J. Med. (1999) 107:48S-54S.
71. RICHY F, BRUYERE O, ETHGEN O et al.: Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann. Rheum. Dis. (2004) 63:759-766.
72. SINGH G, LANES S, TRIADAFILOPUOLOS G: Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam. Am. J. Med. (2004) 117:100-106.
73. HAWKEY C, KAHAN A, STEINBRUCK K et al.: Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. Br. J. Rheumatol. (1998) 37:937-945.
74. DEQUEKER J, HAWKEY C, KAHAN A et al: Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxiciam: results of the safety and efficacy large-scale evaluation of COX-inhibiting therapies (SELECT) trial in osteoarthritis. Br. J. Rheumatol. (1998) 37:946-951.
75. MARTIN RM, BISWAS P, MANN RD: The incidence of adverse events and risk factors for upper gastrointestinal disorders associated with meloxicam use amongst 19,087 patients in general practice in England: cohort study. Br. J. Clin. Pharmacol. (2000) 50:35-42.
76. JICK SS: The risk of gastrointestinal bleed, myocardial infarction, and newly diagnosed hypertension in users of meloxicam, diclofenac, naproxen, and piroxicam. Pharmacotherapy (2000) 20:741-744.
77. LAPORTE JR, IBANEZ L, VIDAL X, VENDRELL L, LEONE R: Upper gastrointestinal bleeding associated with the use of NSAIDs. Drug Saf. (2004) 27:411-420.
78. DEGNER F, SIGMUND R, ZEIDLER H: Efficacy and tolerability of meloxicam in an observational, controlled cohort study in patients with rheumatic disease. Clin. Ther. (2000) 22:400-410.
79. MACDONALD TM, MORANT SV, GOLDSTEIN JL, BURKE TA, PETTITT D: Channeling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs. Gut (2003) 52:1265-1270.
80. MORANT SV. PETTITT D, MACDONALD TM, BURKE TA GOLDSTEIN JL: Application of a propensity score to adjust for channeling bias with NSAIDs. Pharmacoepidemiol. Drug Saf. (2004) 13:345-353.
81. LAYTON D, HEELEY E, HUGHES K, SHAKIR SAW: Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring data. Rheumatology (2003) 42:622-631.
82. LAYTON D, HUGHES K, HARRIS S, SHAKIR SAW: Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring data (PEM). Rheumatology (2003) 42:1332-1341.
83. LAYTON D, HEELEY E, HUGHES K, SHAKIR SAW: Comparison of the incidence rates of thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Rheumatology (2003) 42:1342-1353.
84. LAYTON D, HUGHES K, HARRIS S, SHAKIR SAW: Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Rheumatology (2003) 42:1354-1364.
85. ALTMAN R, LUCIARDI HL, MUNTANER J et al.: Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation - The nonsteroidal anti-inflammatory drugs in unstable angina treatment-2 (NUT-2) pilot study. Circulation (2002) 106:191-195.
86. BARNER A: Review of clinical trials and benefit/risk ratio of meloxicam. Scand. J. Rheumatol. (1996) 25:29-37.
87. NETTIS E, DI PAOLA R, FERRANNINI A, TURSI A: (letter) Allergy (2001) 56:803-804.
88. QUARATINO D, ROMANO A, DI FONSO M et al.: Tolerability of meloxicam in patients with histories of adverse reactions to nonsteroidal anti-inflammatory drugs. Ann. Allergy Asthma Immunol. (2000) 84:613-617.
89. BAVBEK S, CELIK G, OZER F, MUNGAN D, MISIRLIGII Z: Safety of selective COX-2 inhibitors in aspirin/nonsteroidal anti-inflammatory drug-intolerant patients: comparison of nimesulide, meloxicam, and rofecoxib. J. Asthma (2004) 41:67-75.